Brii Biosciences Limited
Brii Biosciences Limited focuses on developing therapies for the treatment of infectious and central nervous system diseases in China and the United States. The company develops BRII-179, a recombinant protein-based HBV immunotherapeutic candidate; Elebsiran, an investigational subcutaneously administered HBV-targeting siRNA; and Tobevibart, an investigational subcutaneously administered HBV-neut… Read more
Brii Biosciences Limited (BRIBF) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of December 2024: -0.028x
Based on the latest financial reports, Brii Biosciences Limited (BRIBF) has a cash flow conversion efficiency ratio of -0.028x as of December 2024.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-73.55 Million) by net assets ($2.61 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Brii Biosciences Limited - Cash Flow Conversion Efficiency Trend (2019–2024)
This chart illustrates how Brii Biosciences Limited's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Brii Biosciences Limited Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Brii Biosciences Limited ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Dar Global Plc
LSE:DAR
|
0.112x |
|
iOCO Limited
JSE:IOC
|
0.353x |
|
Gix Internet Ltd
TA:ALMO
|
0.158x |
|
AnGes Inc
OTCGREY:AMGXF
|
-0.355x |
|
Beijing Telesound Electronics Co Ltd
SHE:003004
|
0.017x |
|
908 Devices Inc
NASDAQ:MASS
|
0.009x |
|
BV Financial, Inc. Common Stock
NASDAQ:BVFL
|
0.046x |
|
Zhejiang Meishuo Electric Technology Co. Ltd. A
SHE:301295
|
N/A |
Annual Cash Flow Conversion Efficiency for Brii Biosciences Limited (2019–2024)
The table below shows the annual cash flow conversion efficiency of Brii Biosciences Limited from 2019 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $2.61 Billion | $-372.89 Million | -0.143x | +25.99% |
| 2023-12-31 | $3.07 Billion | $-594.01 Million | -0.193x | -23.01% |
| 2022-12-31 | $3.16 Billion | $-496.28 Million | -0.157x | +40.82% |
| 2021-12-31 | $3.31 Billion | $-879.46 Million | -0.266x | -214.65% |
| 2020-12-31 | $-1.74 Billion | $-403.72 Million | 0.232x | +111.00% |
| 2019-12-31 | $-612.76 Million | $-67.28 Million | 0.110x | -- |